Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Sorafenib
Cat. No.:
OB0225LY-0398
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Sorafenib is a tyrosine kinase inhibitor that interferes with the growth signals of tumor cells.
Synonym:
Bay 43-9006; 284461-73-0; Nexavar; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
CAS No.:
284461-73-0
Compound CID:
216239
Formula:
C21H16ClF3N4O3
Formula Weight:
464.82
Specification
Relative Density:
1.455. Temperature: 20.
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Sorafenib can be used in cancer research, especially in the study of regulating the tumor microenvironment and tumor cell signaling pathways.
Library Information
Targets:
Kinases
Receptors:
B-Raf; c-Kit; FLT3; mPDGFRβ; PDGFRβ; Raf-1; VEGFR2; VEGFR3; VEGFR4
Pathways:
Apoptosis; MAPK; Autophagy; Tyrosine kinase/adaptors; Angiogenesis
Plate Number:
AOCL-6
Plate Location:
b4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Special Max Solubility:
DMF: 3.33 mg/mL
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.9 mg/mL (12.69 mM)
ALogP:
4.175
HBA_Count:
4
HBD_Count:
3
Rotatable Bond:
6
